Compare CTVA & BSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CTVA | BSX |
|---|---|---|
| Founded | 1802 | 1979 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Farming/Seeds/Milling | Medical/Dental Instruments |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 56.6B | 65.8B |
| IPO Year | 2018 | 2010 |
| Metric | CTVA | BSX |
|---|---|---|
| Price | $89.60 | $45.53 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 16 | 22 |
| Target Price | $84.13 | ★ $93.18 |
| AVG Volume (30 Days) | 2.8M | ★ 17.4M |
| Earning Date | 05-05-2026 | 04-22-2026 |
| Dividend Yield | ★ 0.91% | N/A |
| EPS Growth | 23.08 | ★ 55.20 |
| EPS | ★ 1.07 | 0.90 |
| Revenue | ★ $17,401,000,000.00 | $9,076,000,000.00 |
| Revenue This Year | $6.09 | $11.85 |
| Revenue Next Year | $3.28 | $10.16 |
| P/E Ratio | $84.61 | ★ $51.16 |
| Revenue Growth | 2.92 | ★ 12.49 |
| 52 Week Low | $60.54 | $42.20 |
| 52 Week High | $90.97 | $109.50 |
| Indicator | CTVA | BSX |
|---|---|---|
| Relative Strength Index (RSI) | 68.73 | 54.58 |
| Support Level | $77.96 | $42.23 |
| Resistance Level | N/A | $46.37 |
| Average True Range (ATR) | 1.88 | 1.44 |
| MACD | 0.15 | 0.53 |
| Stochastic Oscillator | 94.49 | 77.50 |
Corteva is an agricultural inputs pure play that was formed in 2019 when it was spun off from DowDuPont. The company is a leader in the development of new seed and crop protection products. Seeds generate the majority of profits with the remainder coming from crop protection products. Corteva plans to spin off its seeds business in late 2026. The seeds business will be named Vylor, while the crop protection business will retain the Corteva name and be a pure-play crop protection company following the divestiture. Corteva operates globally, but around half of revenue comes from North America.
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for roughly 36% of the firm's total sales.